Adventrx Pharmaceuticals Inc. (ANX) announced that it has entered into a multi-year agreement with Patheon Inc. under which Patheon will formulate, fill and finish ANX-188 drug product for use in clinical trials, including the phase 3 study of ANX-188 that Adventrx plans to initiate this year.
For comments and feedback: editorial@rttnews.com